Fennec Pharmaceuticals Inc. (FRX.TO)
CAD 8.55
(0.0%)
CAD 8.55
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 26.86 Million USD | -0.28% |
| 2022 | 26.93 Million USD | 20.19% |
| 2021 | 22.41 Million USD | -28.66% |
| 2020 | 31.41 Million USD | 122.09% |
| 2019 | 14.14 Million USD | -38.36% |
| 2018 | 22.95 Million USD | -19.19% |
| 2017 | 28.4 Million USD | 615.03% |
| 2016 | 3.97 Million USD | 289.79% |
| 2015 | 1.01 Million USD | -57.04% |
| 2014 | 2.37 Million USD | 35.39% |
| 2013 | 1.75 Million USD | -25.92% |
| 2012 | 2.36 Million USD | -55.8% |
| 2011 | 5.35 Million USD | -10.71% |
| 2010 | 5.99 Million USD | 619.45% |
| 2009 | 833 Thousand USD | -86.25% |
| 2008 | 6.06 Million USD | -64.79% |
| 2007 | 17.2 Million USD | 3.77% |
| 2006 | 16.58 Million USD | -41.7% |
| 2005 | 28.44 Million USD | 0.0% |
| 2003 | 41.73 Million USD | 62.65% |
| 2002 | 25.65 Million USD | 276.42% |
| 2001 | 6.81 Million USD | -34.8% |
| 2000 | 10.45 Million USD | 1525.51% |
| 1999 | 643.19 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 69.19 Million USD | 157.57% |
| 2024 Q2 | 63.16 Million USD | -8.72% |
| 2023 FY | 26.86 Million USD | -0.28% |
| 2023 Q3 | 19.02 Million USD | -2.1% |
| 2023 Q4 | 26.86 Million USD | 41.18% |
| 2023 Q1 | 21.82 Million USD | -19.0% |
| 2023 Q2 | 19.43 Million USD | -10.93% |
| 2022 Q2 | 15.56 Million USD | -18.7% |
| 2022 Q1 | 19.14 Million USD | -14.57% |
| 2022 Q3 | 30.41 Million USD | 95.38% |
| 2022 Q4 | 26.93 Million USD | -11.43% |
| 2022 FY | 26.93 Million USD | 20.19% |
| 2021 Q2 | 28.11 Million USD | 1.04% |
| 2021 Q4 | 22.41 Million USD | -13.84% |
| 2021 FY | 22.41 Million USD | -28.66% |
| 2021 Q3 | 26.01 Million USD | -7.47% |
| 2021 Q1 | 27.82 Million USD | -11.43% |
| 2020 Q2 | 39.31 Million USD | 279.21% |
| 2020 Q3 | 34.07 Million USD | -13.34% |
| 2020 Q4 | 31.41 Million USD | -7.79% |
| 2020 FY | 31.41 Million USD | 122.09% |
| 2020 Q1 | 10.36 Million USD | -26.71% |
| 2019 Q1 | 20.65 Million USD | -9.99% |
| 2019 Q3 | 15.9 Million USD | -10.78% |
| 2019 Q4 | 14.14 Million USD | -11.07% |
| 2019 Q2 | 17.82 Million USD | -13.69% |
| 2019 FY | 14.14 Million USD | -38.36% |
| 2018 Q4 | 22.95 Million USD | -7.96% |
| 2018 Q1 | 26.83 Million USD | -5.51% |
| 2018 FY | 22.95 Million USD | -19.19% |
| 2018 Q2 | 25.7 Million USD | -4.22% |
| 2018 Q3 | 24.93 Million USD | -2.99% |
| 2017 Q2 | 10.25 Million USD | 212.01% |
| 2017 FY | 28.4 Million USD | 615.03% |
| 2017 Q4 | 28.4 Million USD | 187.23% |
| 2017 Q3 | 9.88 Million USD | -3.62% |
| 2017 Q1 | 3.28 Million USD | -17.22% |
| 2016 Q4 | 3.97 Million USD | -13.28% |
| 2016 FY | 3.97 Million USD | 289.79% |
| 2016 Q2 | 5.1 Million USD | 768.03% |
| 2016 Q1 | 588 Thousand USD | -42.3% |
| 2016 Q3 | 4.58 Million USD | -10.27% |
| 2015 Q4 | 1.01 Million USD | -29.72% |
| 2015 Q1 | 1.94 Million USD | -17.83% |
| 2015 Q3 | 1.45 Million USD | -22.5% |
| 2015 FY | 1.01 Million USD | -57.04% |
| 2015 Q2 | 1.87 Million USD | -4.0% |
| 2014 FY | 2.37 Million USD | 35.39% |
| 2014 Q4 | 2.37 Million USD | 252.45% |
| 2014 Q3 | 673 Thousand USD | -35.84% |
| 2014 Q2 | 1.04 Million USD | -24.8% |
| 2014 Q1 | 1.39 Million USD | -20.38% |
| 2013 Q2 | 1.03 Million USD | -46.85% |
| 2013 Q1 | 1.93 Million USD | -18.05% |
| 2013 FY | 1.75 Million USD | -25.92% |
| 2013 Q4 | 1.75 Million USD | 173.75% |
| 2013 Q3 | 640 Thousand USD | -37.86% |
| 2012 Q1 | 4.75 Million USD | -11.1% |
| 2012 FY | 2.36 Million USD | -55.8% |
| 2012 Q3 | 2.93 Million USD | -18.61% |
| 2012 Q2 | 3.6 Million USD | -24.32% |
| 2012 Q4 | 2.36 Million USD | -19.28% |
| 2011 Q1 | 7.63 Million USD | 27.43% |
| 2011 FY | 5.35 Million USD | -10.71% |
| 2011 Q4 | 5.35 Million USD | -14.67% |
| 2011 Q3 | 6.27 Million USD | -8.18% |
| 2011 Q2 | 6.83 Million USD | -10.57% |
| 2010 Q4 | 5.99 Million USD | -9.24% |
| 2010 Q2 | 7156.00 USD | -98.48% |
| 2010 Q1 | 470 Thousand USD | -43.58% |
| 2010 FY | 5.99 Million USD | 619.45% |
| 2010 Q3 | 6.6 Million USD | 92172.22% |
| 2009 Q4 | 833 Thousand USD | -10.14% |
| 2009 Q2 | 1.69 Million USD | -47.67% |
| 2009 Q3 | 927 Thousand USD | -45.44% |
| 2009 Q1 | 3.24 Million USD | -46.42% |
| 2009 FY | 833 Thousand USD | -86.25% |
| 2008 Q3 | 8.65 Million USD | -22.66% |
| 2008 Q1 | 14.2 Million USD | -17.47% |
| 2008 Q4 | 6.06 Million USD | -30.01% |
| 2008 Q2 | 11.19 Million USD | -21.18% |
| 2008 FY | 6.06 Million USD | -64.79% |
| 2007 Q2 | 21.66 Million USD | -7.56% |
| 2007 FY | 17.2 Million USD | 3.77% |
| 2007 Q4 | 17.2 Million USD | -11.57% |
| 2007 Q3 | 19.46 Million USD | -10.18% |
| 2007 Q1 | 23.43 Million USD | 41.32% |
| 2006 FY | 16.58 Million USD | -41.7% |
| 2006 Q4 | 16.58 Million USD | -26.09% |
| 2006 Q3 | 22.43 Million USD | -15.05% |
| 2006 Q2 | 26.41 Million USD | 7.08% |
| 2006 Q1 | 24.66 Million USD | -13.28% |
| 2005 Q4 | 28.44 Million USD | -21.28% |
| 2005 FY | 28.44 Million USD | 0.0% |
| 2005 Q2 | 32.45 Million USD | -8.44% |
| 2005 Q3 | 36.13 Million USD | 11.32% |
| 2005 Q1 | 35.44 Million USD | 0.0% |
| 2004 Q2 | 41.73 Million USD | 15.78% |
| 2004 Q1 | 36.04 Million USD | -9.0% |
| 2004 Q3 | 41.14 Million USD | -1.4% |
| 2003 Q1 | 22.89 Million USD | -1.62% |
| 2003 Q2 | 25.65 Million USD | 12.08% |
| 2003 Q3 | 23.72 Million USD | -7.54% |
| 2003 Q4 | 39.61 Million USD | 66.96% |
| 2003 FY | 41.73 Million USD | 62.65% |
| 2002 FY | 25.65 Million USD | 276.42% |
| 2002 Q3 | 5.68 Million USD | -16.67% |
| 2002 Q1 | 7.62 Million USD | -9.98% |
| 2002 Q4 | 23.27 Million USD | 309.66% |
| 2002 Q2 | 6.81 Million USD | -10.59% |
| 2001 FY | 6.81 Million USD | -34.8% |
| 2001 Q3 | 9.09 Million USD | -12.99% |
| 2001 Q2 | 10.45 Million USD | 0.0% |
| 2001 Q4 | 8.46 Million USD | -6.9% |
| 2000 FY | 10.45 Million USD | 1525.51% |
| 2000 Q4 | 6.05 Million USD | 0.0% |
| 1999 FY | 643.19 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Appili Therapeutics Inc. | 1.49 Million CAD | -1702.466% |
| Eupraxia Pharmaceuticals Inc. | 26.72 Million CAD | -0.527% |
| Helix BioPharma Corp. | 1.48 Million CAD | -1704.164% |
| Microbix Biosystems Inc. | 35.65 Million CAD | 24.652% |
| Medicenna Therapeutics Corp. | 19.13 Million CAD | -40.399% |
| Satellos Bioscience Inc. | 44.29 Million CAD | 39.356% |
| Oncolytics Biotech Inc. | 38.82 Million CAD | 30.799% |
| Sernova Corp. | 22.1 Million CAD | -21.519% |